Inventiva S.A. (IVA): Business Model Canvas

Welcome to a deep dive into the Business Model Canvas of Inventiva S.A. (IVA), a dynamic player in the pharmaceutical landscape. Here, we unravel the intricate layers that define its operations, including key partnerships with research institutions and regulatory bodies, a focus on innovative treatments, and strategies that drive patient engagement and market reach. Discover how Inventiva strategically navigates its quest for effective healthcare solutions and fosters relationships across various customer segments. Join us as we explore the nuances of this robust business model.

Inventiva S.A. (IVA) - Business Model: Key Partnerships

Research Institutions

Inventiva S.A. collaborates with several renowned research institutions to enhance its drug development processes. These partnerships allow Inventiva to leverage cutting-edge scientific research and gain access to innovative technologies.

• Partnership with the University of Strasbourg: Joint research projects focused on fibrosis and dermatology.
• CIC -Clinical Investigation Centre: Provides expertise in clinical methodologies for developing new therapies.
• CRCM - Cancer Research Center: Collaboration for oncology research, aiming to develop new cancer treatments.

Pharmaceutical Suppliers

Suppliers play a crucial role in ensuring the availability of raw materials and active pharmaceutical ingredients (APIs) required for Inventiva's product development.

Supplier	Type of Supply	Contract Value (EUR)	Duration
Fujifilm Diosynth Biotechnologies	Biologics Manufacturing	2,000,000	2 Years
Lonza Group	APIs	1,500,000	3 Years
DSM Sinochem Pharmaceuticals	Raw Materials	1,200,000	1 Year

Clinical Trial Organizations

Inventiva S.A. partners with various clinical trial organizations to ensure efficient and compliant execution of clinical studies, which is essential for regulatory approvals.

• Partnership with PPD (Pharmaceutical Product Development): Engagement for global clinical trial management.
• IQVIA: Partnership for patient recruitment and data analytics during clinical trials.
• Syneos Health: Collaboration to enhance operational efficiencies in clinical operations.

Regulatory Bodies

Collaboration with regulatory bodies ensures that Inventiva’s products meet all necessary standards for safety and efficacy. Key partnerships include:

• EMA (European Medicines Agency): Regular consultations on the approval process for new drugs.
• FDA (U.S. Food and Drug Administration): Engagements during the IND application process for clinical trials in the U.S.
• ANSM (French National Agency for Medicines and Health Products Safety): Ongoing communication regarding compliance and regulatory requirements.

Inventiva S.A. (IVA) - Business Model: Key Activities

Drug Discovery

Inventiva S.A. engages in innovative drug discovery processes, focusing on small molecules that target several diseases, particularly in the therapeutic area of fibrosis and dermatology. Their pipeline includes compounds such as IVA337, targeted for dermatological diseases, and ABBV-181, a collaboration with AbbVie.

As of 2023, the company's discovery phase investment is approximately €10 million annually.

Activity	Target Disease	Investment (€)	Status
IVA337	Dermatological diseases	5,000,000	Preclinical
ABBV-181	Various cancers	5,000,000	Phase I

Clinical Trials

The success of drug development at Inventiva S.A. heavily relies on conducting rigorous clinical trials. In 2022, Inventiva reported the initiation of several clinical trial phases. The costs for these trials were approximately €12 million in the fiscal year.

The following table outlines the key clinical trials currently undertaken by Inventiva:

Trial Name	Phase	Cost (€)	Participants
Trial for IVA337	Phase II	6,000,000	200
Trial for ABBV-181	Phase I	6,000,000	150

Regulatory Approval

Regarding regulatory approval, Inventiva S.A. must comply with stringent European and global regulations. The average timeline for regulatory approval in the pharmaceutical industry can extend for over 10 years. In 2023, the estimated expenditures for regulatory compliance and submission are projected to be around €4 million.

The following table illustrates costs related to regulatory activities:

Activity	Cost (€)	Timeline (Years)
Regulatory Submissions	2,500,000	4
Compliance Activities	1,500,000	2

Marketing and Sales

Marketing and sales are essential to the commercialization of Inventiva's products. An annual marketing budget of approximately €8 million was allocated for 2023, emphasizing targeted outreach to healthcare professionals.

Sales figures post-commercialization generally range significantly; initial projections for IVA337 alone estimate annual sales potential exceeding €100 million within five years after market entry.

The table below summarizes marketing efforts:

Marketing Strategy	Budget (€)	Target Audience
Direct Marketing	3,000,000	Healthcare Professionals
Digital Campaigns	2,000,000	General Public
Conferences & Workshops	1,500,000	Industry Specialists
Market Research	1,500,000	Strategic Development

Inventiva S.A. (IVA) - Business Model: Key Resources

R&D Team

Inventiva S.A. maintains a robust R&D team consisting of approximately 80 highly skilled professionals, focusing on the development of innovative therapies targeting unmet medical needs. The team's expertise spans various fields, including medicinal chemistry, molecular biology, and clinical development.

Laboratory Facilities

Inventiva operates state-of-the-art laboratory facilities located in Daix, France, with a total area of about 3,000 square meters. The facilities are equipped with advanced technologies to support research and development processes.

Facility Type	Area (Square Meters)	Key Equipment
Biochemistry Lab	1,000	High-Throughput Screening Systems
Molecular Biology Lab	800	Sequencers, PCR Machines
Chemistry Lab	900	Fume Hoods, Reactors
Quality Control Lab	300	Analytical Balance, HPLC

Intellectual Property

Inventiva holds a diverse portfolio of intellectual property, including 30+ patents granted globally as of 2023, enhancing its competitive advantage in the pharmaceutical market. Key patents relate to compounds such as:

• CB-103 - for the treatment of various cancers
• IVA337 - a treatment for non-alcoholic steatohepatitis (NASH)

Funding

As of the end of Q3 2023, Inventiva S.A. reported a financial cash position of approximately €35 million. The company has successfully raised capital through various funding rounds:

Funding Round	Amount Raised (in Million €)	Year
Initial Public Offering	30	2017
Private Placement	15	2020
Public Offering	10	2022
Capital Increase	25	2023

Inventiva S.A. (IVA) - Business Model: Value Propositions

Innovative treatments

The value proposition of Inventiva S.A. lies significantly in its innovative treatments. The company focuses on the development of therapies for rare diseases, particularly focusing on diseases related to fibrosis and metabolic disorders. A prime example is the drug candidate, lanifibranor, which targets non-alcoholic steatohepatitis (NASH). As of October 2023, the global NASH market is projected to reach $30 billion by 2026, highlighting the immense potential and demand for effective treatments.

Enhanced effectiveness

Inventiva's research emphasizes treatments that demonstrate enhanced effectiveness compared to existing therapies. Lanifibranor has showcased considerable promise in clinical trials, showing superior efficacy in reducing liver fat compared to placebo. In a Phase II clinical trial, approximately 39% of patients treated with lanifibranor achieved at least a 30% reduction in liver fat, consistent with the drug’s targeted action.

Improved patient outcomes

One of the primary goals of Inventiva is to deliver improved patient outcomes. The company’s clinical development programs are rooted in patient-centric research, aiming to provide therapies that lead to substantial health improvements. With an increasing focus on patient-reported outcomes, the treatment efficacy is evaluated not just on clinical metrics but also through patient experience and quality of life assessments. According to the latest data, over 70% of patients in trials reported significant improvements in health-related quality of life, supporting the value proposition of the company’s offerings.

Competitive pricing

Pricing strategy is crucial for Inventiva's value proposition. The company aims to ensure competitive pricing for its innovative products. In 2022, the average annual cost of treatments for chronic liver diseases ranged from $20,000 to $60,000, whereas Inventiva has targeted a price point that is expected to be 15-20% lower than the market average, enhancing accessibility for patients and healthcare systems. This pricing strategy positions Inventiva to attract a broader customer base while ensuring sustainable profitability.

Factor	Details
Market Projection for NASH	$30 billion by 2026
Percentage reduction in liver fat with Lanifibranor	39%
Patient-reported improvement in health-related quality of life	70%
Target pricing strategy vs. market average treatments	15-20% lower

Inventiva S.A. (IVA) - Business Model: Customer Relationships

Continuous support

Inventiva S.A. emphasizes continuous support as a critical aspect of their customer relationships. They deploy dedicated teams for the management of patient inquiries and issues, ensuring responsive and effective communication, especially during clinical trials and post-market surveillance.

In 2022, the company reported a patient support service satisfaction rate of approximately 92% based on internal surveys conducted among trial participants.

Medical education

The company invests in medical education initiatives aimed at healthcare professionals and patients. In 2023, Inventiva S.A. allocated around €1.5 million toward educational programs and materials, which include workshops and online webinars focused on their innovative therapies.

According to industry standards, effective medical education can improve therapy adherence rates by 20% to 30%, which is an essential metric for patient outcomes.

Feedback mechanisms

Inventiva S.A. has implemented systematic feedback mechanisms to gather insights from customers and healthcare providers. They utilize platforms for collecting data on product effectiveness, ease of use, and overall customer satisfaction.

In 2022, the company achieved a feedback response rate of 75% from healthcare providers in their trials, which significantly informs R&D strategies and enhances customer relationship management.

Feedback Mechanism	Response Rate	Data Utilization
Surveys	80%	Product Improvement
Focus Groups	70%	Development Feedback
Online Forums	60%	Curation of Resources
Direct Interviews	50%	Strategic Insights

Patient assistance programs

Inventiva S.A. operates various patient assistance programs designed to help patients navigate access to therapies. These programs focus on reducing financial burdens associated with treatment and are particularly vital for underinsured or uninsured patients.

In 2023, the company reported that over 3,000 patients benefited from their assistance programs, reflecting a commitment to improving treatment accessibility. The estimated financial support provided in this year alone was valued at around €2 million.

Program Type	Number of Patients Assisted	Estimated Financial Support (€)
Medication Access	1,500	1,000,000
Insurance Navigation	800	600,000
Cost-Savings Strategies	700	400,000

Inventiva S.A. (IVA) - Business Model: Channels

Direct sales

Inventiva S.A. employs a direct sales model to engage with healthcare professionals, hospitals, and clinics. This model allows the company to establish a personal connection with clients, providing tailored solutions that meet specific needs. In 2022, direct sales accounted for approximately 40% of the company’s total revenue. Sales representatives are trained extensively about product offerings, operating in key regions including Europe and the United States.

Pharmaceutical distributors

Through partnerships with pharmaceutical distributors, Inventiva S.A. leverages an established network to reach a broader audience. As of 2023, the global pharmaceutical distribution market is valued at about $600 billion. Inventiva's distribution agreements cover various regions, ensuring that their products are available in multiple markets efficiently. The company reported that approximately 35% of its products reach customers through distributor channels.

Region	Market Share (%)	Distributor Partnerships
North America	25%	5
Europe	30%	7
Asia	15%	4
Latin America	10%	3

Online platforms

Inventiva S.A. also utilizes online platforms for marketing and sales activities. The company's digital strategy includes the use of e-commerce platforms that allow healthcare providers to request information and place orders directly online. In 2022, online sales contributed to 25% of total revenues, highlighting the growing importance of digital channels in the healthcare sector.

Medical conferences

Participation in medical conferences is another critical channel for Inventiva S.A. These events facilitate direct interactions with industry professionals, promoting brand visibility and product knowledge dissemination. In 2022, the company attended over 15 major medical conferences, noting that around 20% of new partnerships originated from these engagements. The estimated budget for participating in such conferences was around $2 million for that year.

Conference Name	Location	Year Attended	New Partnerships Established
European Society of Cardiology	Barcelona, Spain	2022	3
American Diabetes Association	New Orleans, USA	2022	4
World Congress on Osteoporosis	Paris, France	2022	2
International Cancer Research Conference	Tokyo, Japan	2022	3

Inventiva S.A. (IVA) - Business Model: Customer Segments

Healthcare providers

Inventiva S.A. targets a wide range of healthcare providers, including general practitioners, specialists, and integrated care networks. As of 2023, there were approximately 1 million active healthcare providers in the European Union, with a significant growth rate of 3.5% annually.

In the United States, the number of healthcare providers stands at around 1.3 million, underlining a favorable environment for targeted marketing and product distribution.

Hospitals and clinics

Inventiva S.A. collaborates extensively with hospitals and clinics, which account for a substantial portion of their customer base. In Europe, there are approximately 25,000 hospitals, with more than 200,000 clinics, while in the U.S., about 6,200 hospitals operate.

Region	Number of Hospitals	Number of Clinics
Europe	25,000	200,000
United States	6,200	N/A

Hospitals are facing tremendous financial pressures, with average operating margins reported at 2.7% as of 2023. This emphasizes a need for innovative solutions that serve changing healthcare delivery models.

Pharmacies

Inventiva S.A. also targets pharmacies, which play a pivotal role in the distribution of medications and health products. In Europe, there are around 100,000 community pharmacies. In the United States, as of 2023, the number is approximately 88,000.

Pharmacies account for a substantial revenue stream within the healthcare ecosystem. The global pharmacy market was valued at approximately $1 trillion in 2022, with a projected increase of 4% CAGR through 2027.

Patients

End-users or patients represent a crucial segment for Inventiva S.A., especially those suffering from rare diseases and chronic conditions. The global patient population for rare diseases is estimated at around 300 million, with around 7,000 rare diseases identified. In the chronic disease arena, approximately 1.7 billion people worldwide are living with chronic conditions.

Segment	Number of Individuals	Common Conditions
Rare Diseases	300 million	Various (e.g., Cystic Fibrosis, Huntington's Disease)
Chronic Conditions	1.7 billion	Diabetes, Cardiovascular Diseases

The market for patient-oriented solutions is expanding rapidly, with digital health solutions alone expected to reach a market size of approximately $660 billion by 2025.

Inventiva S.A. (IVA) - Business Model: Cost Structure

R&D expenses

The research and development (R&D) expenses of Inventiva S.A. are crucial to their business model, focusing on pharmaceuticals and innovative treatments. In 2022, Inventiva reported R&D expenses amounting to approximately €18.3 million.

Manufacturing costs

Manufacturing costs for Inventiva involve the production of their biopharmaceuticals, which is substantially influenced by their process development and scale-up. Estimated manufacturing costs in 2022 reached around €12 million.

Marketing and sales

Marketing and sales expenses play a significant role in driving awareness and adoption of Inventiva's products. In their latest reports, the company allocated approximately €7.5 million for marketing and sales activities in 2022.

Regulatory compliance

Regulatory compliance costs, which include the expenses related to meeting the requirements of health authorities and obtaining necessary approvals, are critical for Inventiva. In 2022, these costs stood at about €3 million.

Cost Type	2022 Amount (€ million)	Notes
R&D Expenses	18.3	Focus on innovative pharmaceutical products.
Manufacturing Costs	12.0	Includes process development and scale-up.
Marketing and Sales	7.5	Driving awareness and adoption of products.
Regulatory Compliance	3.0	Costs related to meeting health authority requirements.

Inventiva S.A. (IVA) - Business Model: Revenue Streams

Drug Sales

Inventiva S.A. generates revenue through the sales of its pharmaceutical products. In 2022, the company reported revenues of approximately €7.2 million from drug sales, primarily derived from its lead drug candidate, lanifibranor, which targets non-alcoholic steatohepatitis (NASH). Inventiva has focused on addressing unmet medical needs through innovative therapies.

Licensing Fees

Licensing agreements serve as a significant revenue stream. In 2021, Inventiva S.A. obtained a milestone payment of $10 million from AbbVie as part of a licensing agreement for the drug ABBV-181. The company has established several licensing agreements that contribute to its revenue base.

Research Grants

Inventiva S.A. benefits from government and private research grants aimed at advancing pharmaceutical development. For instance, in 2022, the company received €2.5 million in research funding from the French government to support its ongoing clinical trials and R&D initiatives, enhancing its financial stability during product development phases.

Partnerships and Collaborations

Partnerships with larger pharmaceutical companies facilitate additional revenue streams. A notable example is the collaboration with Boehringer Ingelheim, which encompasses a partnership agreement worth up to $25 million depending on achievement of specific development milestones. These collaborations not only provide upfront payments but also revenue through shared profits in marketed products.

Revenue Stream	Year	Amount	Notes
Drug Sales	2022	€7.2 million	Revenue from lanifibranor
Licensing Fees	2021	$10 million	Milestone from AbbVie
Research Grants	2022	€2.5 million	French government funding
Partnerships and Collaborations	2021	$25 million	Boehringer Ingelheim collaboration